You are here

orphan drugs

Report: Evaluating the Cost-Effectiveness and Controversies of Orphan Drugs

Report: Evaluating the Cost-Effectiveness and Controversies of Orphan Drugs

BioSpace

Orphan Drug Act

Flag link:

Clinical Costs for Orphan Drugs Lower Than Non-Orphan Drugs, Study Finds

Clinical Costs for Orphan Drugs Lower Than Non-Orphan Drugs, Study Finds

RAPS.org

Flag link:

New Industry Report Finds Most Orphan Drugs Aren't Successful

New Industry Report Finds Most Orphan Drugs Aren't Successful

BioSpace

Flag link:

FDA Faulted For Lapses In Orphan Drug Program

FDA Faulted For Lapses In Orphan Drug Program

NPR

Flag link:

Astrazeneca's Fasenra Gets Orphan Drug Designation for Autoimmune Disease

Astrazeneca's Fasenra Gets Orphan Drug Designation for Autoimmune Disease

Yahoo/Zacks.com

eosinophilic granulomatosis with polyangiitis

Flag link:

Failed as a Cancer Treatment - Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1

Failed as a Cancer Treatment - Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1

CP Wire

Array Biopharma

neurofibromatosis

Flag link:

FDA Finalizes Guidance Closing Pediatric Study Loophole

FDA Finalizes Guidance Closing Pediatric Study Loophole

RAPS.org

Flag link:

Inozyme Pharma Receives Orphan Drug Designation for INZ-701 in the United States and European Union

Inozyme Pharma Receives Orphan Drug Designation for INZ-701 in the United States and European Union

CP Wire

Flag link:

Seattle Genetics Announces Results of Two Ph II Trials of Tucatinib in HER2- Positive Metastatic Breast Cancer

Seattle Genetics Announces Results of Two Ph II Trials of Tucatinib in HER2- Positive Metastatic Breast Cancer

CP Wire

Seattle Genetics

clinical trials

HER2-positive metastatic breast cancer

Flag link:

Tetra Discovery Partners Initiates Ph II Trial of Fragile X Syndrome Drug

Tetra Discovery Partners Initiates Ph II Trial of Fragile X Syndrome Drug

CP Wire

Tetra Discovery Partners

Fragile X syndrome

clinical trials

Flag link:

Eagle Receives Orphan Drug Designation for Bendeka

Eagle Receives Orphan Drug Designation for Bendeka

CP Wire

Eagle Pharmaceuticals

Flag link:

Are Orphan Drugs Getting Too Much Attention By Payers And Policymakers?

Are Orphan Drugs Getting Too Much Attention By Payers And Policymakers?

Forbes

Flag link:

5 Best-Selling Orphan Drugs in the U.S.

5 Best-Selling Orphan Drugs in the U.S.

Motley Fool

Teva Pharmaceutical

Bristol-Myers Squibb

Flag link:

Half of orphan drug sales to come from cancer, Evaluate finds

Half of orphan drug sales to come from cancer, Evaluate finds

Biopharma Dive

Flag link:

Orphan drugs to grow twice as fast as rest of the industry: report

Orphan drugs to grow twice as fast as rest of the industry: report

Medical Marketing and Media

Flag link:

Market Exclusivity is not What Attracts Orphan Drug Investment, Research Finds

Market Exclusivity is not What Attracts Orphan Drug Investment, Research Finds

RAPS.org

market exclusivity

Flag link:

Eloxx Receives Another Orphan-Drug Designation for ELX-02

Eloxx Receives Another Orphan-Drug Designation for ELX-02

CP Wire

Eloxx Pharmaceuticals

Flag link:

EU Advisory Group Backs Orphan Drug Designation for Alnylam's ALN-TTRsc02 for ATTR Amyloidosis

EU Advisory Group Backs Orphan Drug Designation for Alnylam's ALN-TTRsc02 for ATTR Amyloidosis

CP Wire

ATTR amyloidosis

Flag link:

No slowing down: Orphan drug designations skyrocket in 2017

No slowing down: Orphan drug designations skyrocket in 2017

Medical Marketing and Media

Flag link:

Analyzing the orphan drugs market ($127bn)

Analyzing the orphan drugs market ($127bn)

GoinPharma

Flag link:

Pages